



Collaboration with PATH for the development of Intercell's *Streptococcus pneumoniae* vaccine

- » Support from PATH for the development of Intercell's *Streptococcus pneumoniae* candidate vaccine – USD 7.3 m initial funding through preclinical stage, leading to a vaccine candidate ready to enter clinical trials
- » Pneumococcus causes pneumonia and sepsis – it is a major life-threatening pathogen that is a particular risk for children and the elderly.
- » Intercell and PATH will develop the vaccine protecting against the majority of pneumococcal strains and make it available at an affordable cost for children in certain developing world countries. Intercell will retain all rights in developed countries.

September 6, 2006 (Vienna, Austria) – Intercell and PATH, a US-based non-profit organization dedicated to finding solutions for global health issues today announced an agreement to advance the development of Intercell's *Streptococcus pneumoniae* vaccine. Intercell will receive a total of USD 7.3 m during the first stage of the collaboration, with the potential for substantial additional funding during later development phases. Intercell and PATH are committed to work together towards the successful development of the vaccine in clinical trials leading to registration and market approval.

PATH will provide funding to support Intercell's ongoing *Streptococcus pneumoniae* ("Pneumococcus") protein-based vaccine development program, facilitating the completion of preclinical work. This program is derived from Intercell's proprietary antigen discovery technology, AIP®, and targets a major worldwide cause of pneumonia, bacterial sepsis and meningitis.

Under the terms of the collaboration, Intercell will develop the vaccine and make it available at an affordable cost for children in developing World countries at greatest need, where Pneumococcus is a major cause of infant and childhood mortality. Worldwide, more than 1 million people die each year from pneumococcal infections; children under 5 years of age account for the majority of these deaths. Intercell retains all rights in developed countries for the childhood formulation of the pneumococcal vaccine and also retains as a key aim the rights for an adult formulation of the same product, designed to prevent pneumococcal infection in the elderly. Current vaccines on the market cover only a limited number of pneumococcal strains, especially outside the US, and also are not affordable to countries in the developing World.

“We are delighted that PATH, after an extensive review of the field, has selected our vaccine as one of the most promising novel approaches to prevent *Streptococcus pneumoniae* infection. The experience and commitment of PATH will be an extremely valuable asset to Intercell and we look forward to working with the group as we advance the project towards the clinic”, states Gerd Zettlmeissl, CEO of Intercell AG.



“Intercell’s innovative protein-based vaccine is a promising candidate for protecting children in the developing world,” notes John Boslego, director of pneumococcal vaccine development at PATH. “We at PATH are particularly interested in developing a vaccine containing proteins which are common to all pneumococcus serotypes because such a ‘common protein’ vaccine could provide broad protection to children worldwide.”

About PATH

PATH is a US-based nonprofit organization with over 27 years experience in global health. Headquartered in Seattle, PATH's mission is to improve the health of people around the world. PATH works on a wide array of emerging and persistent global health issues, including children's health, infectious diseases and vaccines and immunization.

In April 2006, PATH announced the launch of its pneumococcal protein vaccine effort aimed at accelerating development of a vaccine that is capable of addressing a broad range of strains of pneumococcus, a bacterium that causes pneumonia. The program is supported by a grant from the Bill & Melinda Gates Foundation with a five-year US \$75 million grant. For more information on PATH, please visit www.path.org.

About Intercell AG

Intercell AG is a biotechnology company focused on the research, development, manufacturing and future commercialization of innovative vaccines for the prevention and treatment of infectious diseases, for which there exists a substantial unaddressed medical need. Intercell develops antigens and immunizers (adjuvants), which are derived from its proprietary technology platforms and has in-house GMP manufacturing capability. Intercell has strategic partnerships with a number of global pharmaceutical companies, including Novartis, Sanofi Pasteur S.A., Merck & Co., Inc., Kirin Brewery Co., Ltd. and the Statens Serum Institut. Intercell has a broad development pipeline with a vaccine product candidate for Japanese Encephalitis in Phase III clinical trials, a vaccine product candidate for Hepatitis C in Phase II, partnered vaccine candidates for Tuberculosis and *S. aureus*, which are in Phase I, and more than five other product candidates focused on infectious diseases in pre-clinical development. Intercell is listed on the Vienna stock exchange under the symbol "ICLL".

For more information, please visit: www.intercell.com



Contact Intercell AG:

Intercell AG

Katharina Wieser

Head of Corporate Communications

Campus Vienna Biocenter 2, A-1030 Vienna

P: +43-1-20620-303

Mail to: kwieser@intercell.com

This communication expressly or implicitly contains certain forward-looking statements concerning Intercell AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Intercell AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Intercell AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.